Health Care [ 6/12 ] | Pharmaceuticals [ 39/74 ]
NASDAQ | Common Stock
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer.
It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F.
Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 3, 25 | -0.15 Increased by +31.82% | -0.20 Increased by +23.08% |
| Nov 7, 24 | -0.18 Increased by +25.00% | -0.21 Increased by +14.29% |
| Aug 8, 24 | -0.25 Increased by +7.41% | -0.20 Decreased by -25.00% |
| May 9, 24 | -0.19 Increased by +40.63% | -0.19 |
| Mar 4, 24 | -0.22 Increased by +31.25% | -0.21 Decreased by -4.76% |
| Nov 7, 23 | -0.24 Increased by +22.58% | -0.20 Decreased by -20.00% |
| Aug 8, 23 | -0.27 Increased by +68.24% | -0.28 Increased by +3.57% |
| May 9, 23 | -0.32 Increased by +34.69% | -0.25 Decreased by -28.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 29.18 M Increased by +22.15% | 7.26 M Increased by +117.26% | Increased by +24.89% Increased by +114.13% |
| Sep 30, 24 | 24.12 M Decreased by -0.08% | -37.06 M Increased by +19.15% | Decreased by -153.61% Increased by +19.09% |
| Jun 30, 24 | 23.49 M Increased by +14.59% | -52.36 M Decreased by -2.43% | Decreased by -222.93% Increased by +10.61% |
| Mar 31, 24 | 21.64 M Increased by +0.21% | -36.80 M Increased by +73.14% | Decreased by -170.07% Increased by +73.20% |
| Dec 31, 23 | 23.89 M Increased by +8.45% | -42.08 M Increased by +29.50% | Decreased by -176.17% Increased by +35.00% |
| Sep 30, 23 | 24.14 M Increased by +2.20% | -45.84 M Increased by +22.37% | Decreased by -189.85% Increased by +24.04% |
| Jun 30, 23 | 20.50 M Decreased by -5.03% | -51.12 M Increased by +67.86% | Decreased by -249.39% Increased by +66.16% |
| Mar 31, 23 | 21.59 M Decreased by -13.00% | -137.02 M Decreased by -51.58% | Decreased by -634.52% Decreased by -74.24% |